FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2037192945> ?p ?o ?g. }

• W2037192945 endingPage "1551" @default.
• W2037192945 startingPage "1542" @default.
• W2037192945 abstract "Propafenone is a new class Ic antiarrhythmic compound with a broad pharmacologic profile. In this study, its dose-response relationship was examined in a double-blind, randomized, placebo-controlled five treatment parallel design protocol. Patients enrolled had heart disease with Lown grade 2 premature ventricular contractions (PVCs) (≥30/hr) documented on 24-hour Holter recordings. Propafenone was compared in four doses (337.5, 450, 675, and 900 mg/day) to placebo. The double-blind phase lasted 2 weeks. Two hundred twenty-six patients were enrolled, of whom 171 were men and 55 were women; their mean age was 59.8 years and 85% were Caucasian and 4% were black. The arrhythmias were symptomatic in 173. Twenty (8.8%) withdrew from the study before completion: 15 had adverse reactions, two had intercurrent illnesses, and three withdrew for administrative reasons. In one patient, the density of arrhythmia appeared to increase with propafenone. Side effects were of central nervous system or gastrointestinal origin; less than 5% of patients developed first-degree atrioventricular block or intraventricular conduction defect. There were no deaths in the study. The occurrence of side effects was not related to dose. Propafenone had no effect on heart rate. It increased the PR interval at all doses (9% to 22% compared to placebo at baseline; p < 0.01) at 450 to 900 mg/day after 2 weeks of therapy. The drug increased the QRS duration at all doses, highly significantly at 675 mg/day (8.5 msec; p < 0.01) and at 900 mg/day (15.7 msec; p < 0.01) after 2 weeks of therapy. Only at the highest dose was the QTc slightly but significantly (14.3 msec; p < 0.01) increased. Propafenone exerted a dose-dependent effect on PVCs recorded on serial 24-hour Holter recordings: compared to placebo, at 2 weeks 337.5 mg/day reduced PVCs by 70.8% (p < 0.05), 450 mg/day reduced PVCs by 82.0% (p < 0.01), 675 mg/day reduced PVCs by 90.2% (p < 0.01) and 900 mg/day reduced PVCs by 95.3% (p < 0.01). The effects of the two highest doses of propafenone were significantly greater than those of 337.5 mg/day. In 68% of the patients receiving 900 mg/day, 80% or greater reduction in total PVCs was found. In addition, there was a greater than 90% decrease in ventricular couplets, and 96% decrease in ventricular tachycardia (VT) beats. Propafenone eliminated PVCs in 8% of all patients, ventricular couplets in 58%, and VT beats in 91%. The median percentage of hours in which propafenone reduced PVCs by over 80% increased as a function of drug dose. A dose-response effect of propafenone on PVC suppression was evident during the first 24 hours. The data indicate that propafenone is a potent suppressant of ventricular arrhythmias with a more striking effect on ventricular couplets and VT beats than on total PVCs at a given dose. A significant dose relationship was evident with respect to all parameters of arrhythmia suppression with a low arrhythmogenic potential, excellent tolerability by patients, and a low incidence of drug-induced ECG abnormalities." @default.
• W2037192945 created "2016-06-24" @default.
• W2037192945 creator A5021289229 @default.
• W2037192945 creator A5037182975 @default.
• W2037192945 creator A5049197714 @default.
• W2037192945 creator A5080968099 @default.
• W2037192945 date "1988-12-01" @default.
• W2037192945 modified "2023-10-05" @default.
• W2037192945 title "Effects of propafenone on ventricular arrhythmias: Double-blind, parallel, randomized, placebo-controlled dose-ranging study" @default.
• W2037192945 cites W1900460967 @default.
• W2037192945 cites W1925377509 @default.
• W2037192945 cites W1964447673 @default.
• W2037192945 cites W1967943875 @default.
• W2037192945 cites W1971236307 @default.
• W2037192945 cites W1979016951 @default.
• W2037192945 cites W1979123475 @default.
• W2037192945 cites W1988631676 @default.
• W2037192945 cites W1992361667 @default.
• W2037192945 cites W1995471966 @default.
• W2037192945 cites W2000233222 @default.
• W2037192945 cites W2012249742 @default.
• W2037192945 cites W2014562798 @default.
• W2037192945 cites W2018783326 @default.
• W2037192945 cites W2019030325 @default.
• W2037192945 cites W2022583605 @default.
• W2037192945 cites W2024190777 @default.
• W2037192945 cites W2026077385 @default.
• W2037192945 cites W2026495651 @default.
• W2037192945 cites W2028167410 @default.
• W2037192945 cites W2036090746 @default.
• W2037192945 cites W2036481850 @default.
• W2037192945 cites W2038296537 @default.
• W2037192945 cites W2040091789 @default.
• W2037192945 cites W2042800847 @default.
• W2037192945 cites W2046001116 @default.
• W2037192945 cites W2050417337 @default.
• W2037192945 cites W2052311341 @default.
• W2037192945 cites W2052857635 @default.
• W2037192945 cites W2053253324 @default.
• W2037192945 cites W2055421488 @default.
• W2037192945 cites W2060208017 @default.
• W2037192945 cites W2076917436 @default.
• W2037192945 cites W2087246394 @default.
• W2037192945 cites W2087410496 @default.
• W2037192945 cites W2091373710 @default.
• W2037192945 cites W2099704024 @default.
• W2037192945 cites W2152871303 @default.
• W2037192945 cites W2153864365 @default.
• W2037192945 cites W2235441195 @default.
• W2037192945 cites W2266461191 @default.
• W2037192945 cites W2275637761 @default.
• W2037192945 cites W2405757664 @default.
• W2037192945 cites W2471446929 @default.
• W2037192945 cites W2474124454 @default.
• W2037192945 cites W2440898645 @default.
• W2037192945 doi "https://doi.org/10.1016/0002-8703(88)90741-7" @default.
• W2037192945 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3057844" @default.
• W2037192945 hasPublicationYear "1988" @default.
• W2037192945 type Work @default.
• W2037192945 sameAs 2037192945 @default.
• W2037192945 citedByCount "22" @default.
• W2037192945 countsByYear W20371929452012 @default.
• W2037192945 countsByYear W20371929452014 @default.
• W2037192945 countsByYear W20371929452015 @default.
• W2037192945 countsByYear W20371929452022 @default.
• W2037192945 crossrefType "journal-article" @default.
• W2037192945 hasAuthorship W2037192945A5021289229 @default.
• W2037192945 hasAuthorship W2037192945A5037182975 @default.
• W2037192945 hasAuthorship W2037192945A5049197714 @default.
• W2037192945 hasAuthorship W2037192945A5080968099 @default.
• W2037192945 hasConcept C111773187 @default.
• W2037192945 hasConcept C118441451 @default.
• W2037192945 hasConcept C126322002 @default.
• W2037192945 hasConcept C142724271 @default.
• W2037192945 hasConcept C164705383 @default.
• W2037192945 hasConcept C178697064 @default.
• W2037192945 hasConcept C197934379 @default.
• W2037192945 hasConcept C204787440 @default.
• W2037192945 hasConcept C27081682 @default.
• W2037192945 hasConcept C2777008848 @default.
• W2037192945 hasConcept C2777953023 @default.
• W2037192945 hasConcept C2778557577 @default.
• W2037192945 hasConcept C2779161974 @default.
• W2037192945 hasConcept C2780040984 @default.
• W2037192945 hasConcept C2780074459 @default.
• W2037192945 hasConcept C2781472538 @default.
• W2037192945 hasConcept C42219234 @default.
• W2037192945 hasConcept C71924100 @default.
• W2037192945 hasConcept C84393581 @default.
• W2037192945 hasConceptScore W2037192945C111773187 @default.
• W2037192945 hasConceptScore W2037192945C118441451 @default.
• W2037192945 hasConceptScore W2037192945C126322002 @default.
• W2037192945 hasConceptScore W2037192945C142724271 @default.
• W2037192945 hasConceptScore W2037192945C164705383 @default.
• W2037192945 hasConceptScore W2037192945C178697064 @default.
• W2037192945 hasConceptScore W2037192945C197934379 @default.
• W2037192945 hasConceptScore W2037192945C204787440 @default.
• W2037192945 hasConceptScore W2037192945C27081682 @default.

• next